Skip to main content

LCD L39995: Pharmacogenomic Testing

LCD L39995, Pharmacogenomic Testing, is the Local Coverage Determination that Wellpoint Federal applies to claims from 10 states (CT, IL, MA, ME, MN, NH, NY, RI and others), effective 2026-04-01 and first in force 2025-07-13. The policy text runs 759 words, and its billing and coding article A59915 lists 768 ICD-10-CM codes that support medical necessity for 43 procedure codes. No other contractor publishes a policy with this title.

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Wellpoint Federal
States and territories
10
CT IL MA ME MN NH NY RI VT WI
Revision effective
2026-04-01
Original effective
2025-07-13
Policy text
759 words
Covered ICD-10 codes (articles)
768

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39995
ContractContractorTypeStates
06101Wellpoint FederalMAC - Part AIL
06201Wellpoint FederalMAC - Part AMN
06301Wellpoint FederalMAC - Part AWI
06102Wellpoint FederalMAC - Part BIL
06202Wellpoint FederalMAC - Part BMN
06302Wellpoint FederalMAC - Part BWI
13101Wellpoint FederalA and B and HHH MACCT
13201Wellpoint FederalA and B and HHH MACNY
13102Wellpoint FederalA and B and HHH MACCT
13202Wellpoint FederalA and B and HHH MACNY
13282Wellpoint FederalA and B and HHH MACNY
13292Wellpoint FederalA and B and HHH MACNY
14411Wellpoint FederalA and B and HHH MACRI
14211Wellpoint FederalA and B and HHH MACMA
14311Wellpoint FederalA and B and HHH MACNH
14511Wellpoint FederalA and B and HHH MACVT
14111Wellpoint FederalA and B and HHH MACME
14112Wellpoint FederalA and B and HHH MACME
14212Wellpoint FederalA and B and HHH MACMA
14312Wellpoint FederalA and B and HHH MACNH
14512Wellpoint FederalA and B and HHH MACVT
14412Wellpoint FederalA and B and HHH MACRI

Billing and coding article A59915: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A59915 (Billing and Coding: Pharmacogenomic Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A59915: Billing and Coding: Pharmacogenomic Testing (Billing and Coding, effective 2026-04-01)

Covered ICD-10-CM codes
768
24 groups
Non-covered ICD-10-CM codes
0
Procedure codes listed
43
Full article
cms.gov record
First 24 covered ICD-10-CM codes in A59915
ICD-10-CMDescription (FY2027)
A03.8Other shigellosis
A03.9Shigellosis, unspecified
A04.4Other intestinal Escherichia coli infections
A15.9Respiratory tuberculosis unspecified
A17.9Tuberculosis of nervous system, unspecified
A18.01Tuberculosis of spine
A18.02Tuberculous arthritis of other joints
A18.03Tuberculosis of other bones
A18.09Other musculoskeletal tuberculosis
A18.10Tuberculosis of genitourinary system, unspecified
A18.11Tuberculosis of kidney and ureter
A18.12Tuberculosis of bladder
A18.13Tuberculosis of other urinary organs
A18.14Tuberculosis of prostate
A18.15Tuberculosis of other male genital organs
A18.16Tuberculosis of cervix
A18.17Tuberculous female pelvic inflammatory disease
A18.18Tuberculosis of other female genital organs
A18.2Tuberculous peripheral lymphadenopathy
A18.31Tuberculous peritonitis
A18.32Tuberculous enteritis
A18.39Retroperitoneal tuberculosis
A18.4Tuberculosis of skin and subcutaneous tissue
A18.50Tuberculosis of eye, unspecified

Procedure codes: 0029U, 0031U, 0032U, 0034U, 0070U, 0071U, 0072U, 0073U, 0074U, 0075U, 0076U, 0286U, 0347U, 0348U, 0349U, 0350U, 0419U, 0434U, 81220, 81225, 81226, 81227, 81230, 81231, 81232, 81247, 81283, 81306, 81328, 81335, 81346, 81350, 81355, 81374, 81377, 81381, 81383, 81401, 81406, 81407 and 3 more in the article.

Coverage indications, limitations and medical necessity

Compliance with the provisions in this LCD may be monitored and addressed through post payment data analysis and subsequent medical review audits.

History/Background and/or General Information

Genetic testing holds the potential to provide great value in improving health outcomes for all individuals. The scope of this LCD includes testing to determine how genes affect the body's response to certain medicines, known as pharmacogenetic, or pharmacogenomic testing. Clinicians face a daunting task to individualize therapies to maximize beneficial outcomes and minimize adverse events and lack of effect. Pharmacogenomic (PGx) testing holds the hope of improved choice of drug therapy for multiple conditions for which drug therapy is appropriate.

A person’s genetic code can influence various steps in drug response. Examples of these steps where genetic variation may influence response include drug receptor type and number, increased or decreased drug uptake, and increased or decreased drug metabolism. Depending on the specific situation, these interactions can result in increased or decreased drug effectiveness as well as adverse drug reactions.

This LCD addresses single gene, multi-gene panels, and combinatorial tests aimed at determining an individual’s drug response.

Definitions

Combinatorial PGx test – a type of multi-gene panel that requires a proprietary algorithm to evaluate pharmacokinetic or pharmacodynamic relationships resulting in drug recommendations or warnings.

Actionable use – A test is considered to have an actionable use when the genotype information may lead to selection of or avoidance of a specific therapy or modification of dosage of a therapy. The selection, avoidance, or dose change must be based on the U.S. Food and Drug Administration (FDA) label for the drug, an FDA warning or safety concern, or a Clinical Pharmacogenetics Implementation Consortium (CPIC) level A or B gene-drug interaction. An intended change in therapy based on the result of a genotyping test that is not supported by one of these sources is not considered an actionable use for the purposes of this LCD.

Covered Indications

Pharmacogenetics testing will be considered medically reasonable and necessary if:

• The patient has a condition where clinical evaluation has determined the need for a medication that has a known gene-drug interaction(s) for which the test results would directly impact the drug management of the patient’s condition; AND

• The test meets evidence standards for genetic testing as evaluated by a scientific, transparent, peer-reviewed process and determined to demonstrate actionability in clinical decision making by CPIC guideline level A or B 1 ; or is listed in the FDA table of known gene-drug interactions where data support therapeutic recommendations or a potential impact on safety or response or the FDA label; https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling ; https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations

Some panel/combinatorial tests may include content that has demonstrated actionability and some that has not. In these circumstances, the components of the tests that have demonstrated actionability as noted in #2 will be considered medically reasonable and necessary. Refer to the related billing and coding article for coding information.

Please refer to National Coverage Determination (NCD ) 90.1 for anticoagulation dosing with warfarin.

Limitations

The following is considered not medically reasonable and necessary:

• Genetic testing where either analytical validity, clinical validity, or clinical utility has not been established.

• Germline testing may be performed once in a lifetime per beneficiary.

• Any laboratory test that investigates the same germline genetic content, for the same genetic information, that has already been tested in the same Medicare beneficiary is not medically reasonable and necessary as it is duplicative. The germline sequence of an individual does not change over time, and therefore repeat testing of the same germline content for the same genetic information does not provide new clinical information.

Provider Qualifications

The ordering provider of a PGx test for a patient with a medical condition:

• Must be the treating clinician who is responsible for the pharmacologic management of the patient’s condition. The ordering provider of a PGx test is restricted to providers who have the licensure, qualifications, and necessary experience/training to both diagnose the condition being treated and to prescribe medications (the provider must be able to do both) for the condition either independently or in an arrangement as required by all the applicable state laws; and

• is considering or has already prescribed a pharmacologic treatment with actionable gene-drug interactions; and

• understands the actionability of the ordered test.

Notice: Services performed for any given diagnosis must meet all of the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

Summary of evidence (opening)

Introduction

The purpose of this evidence review is to examine genetic testing used to inform drug therapies and determine if the evidence is sufficient to draw conclusions about better health outcomes for the Medicare population. Generally, key health outcomes include patient survival and disease incidence, along with quality of life and daily functioning. A standardized assessment of analytical validity, clinical validity, and clinical utility should be thoroughly explained and should indicate the confidence level that the test's performance will directly benefit patients. Tests that prove analytical and clinical validity, along with demonstrated clinical utility that inspires confidence in enhancing clinician decision-making, have the potential to change clinical management and improve patient outcomes. Optimal patient outcomes show reduced mortality and morbidity, as well as enhanced quality of life and functionality.

Pharmacogenomic (PGx) testing aims to enhance patient outcomes by optimizing medication selection, thus minimizing ineffective medication use and reducing adverse events. The desired outcomes remain the same patient-centered results mentioned above.

Internal Technology Assessment

The contractor cites 17 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2025-07-13
Current revision effective
2026-04-01
Last reviewed by the contractor
2024-12-28
MCD version
6

The contractor lists one National Coverage Determination as related: NCD 90.1 Pharmacogenomic Testing for Warfarin Response. Where an NCD speaks, it controls; the LCD can only address what the NCD leaves open.

Other related documents: A59982 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Wellpoint Federal hub lists every other active policy from the same contractor.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39995 cover?

Genetic testing holds the potential to provide great value in improving health outcomes for all individuals. The scope of this LCD includes testing to determine how genes affect the body's response to certain medicines, known as pharmacogenetic, or pharmacogenomic testing. Clinicians face a daunting task to individualize therapies to maximize beneficial outcomes and minimize adverse events and lack of effect. The full 759-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39995 apply to?

Wellpoint Federal applies it to Medicare claims in 10 states: CT, IL, MA, ME, MN, NH, NY, RI, VT, WI. It binds only that contractor; outside these jurisdictions the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39995?

The companion billing and coding article A59915 lists 768 ICD-10-CM codes in 24 groups that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L39995?

A denial under LCD L39995 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A59915's 768 covered diagnosis codes, then file a redetermination with Wellpoint Federal within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.